Midsize biotech companies met with White House and HHS officials to urge changes to pending Centers for Medicare & Medicaid Services (CMS) pricing models, arguing the rules could hinder business. The push reflects continued regulatory and reimbursement friction that investors and drug developers closely monitor, particularly for therapies facing uncertain launch economics. The development highlights how biopharma’s near-term funding and commercialization plans are increasingly tied to pricing-policy execution as CMS models move toward finalization.